Vertrix Wealth Management LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Vertrix Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, Holdings Channel reports. The fund purchased 5,806 shares of the medical research company’s stock, valued at approximately $2,854,000.

A number of other large investors have also recently bought and sold shares of TMO. Assetmark Inc. boosted its holdings in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the period. Mackenzie Financial Corp increased its stake in shares of Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after purchasing an additional 62,790 shares during the period. North Dakota State Investment Board acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $7,505,000. Quadrant Capital Group LLC grew its holdings in Thermo Fisher Scientific by 30.9% in the 3rd quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock valued at $6,924,000 after buying an additional 3,369 shares during the last quarter. Finally, EdgePoint Investment Group Inc. increased its position in Thermo Fisher Scientific by 5.0% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock worth $673,529,000 after buying an additional 65,597 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMO has been the topic of several research analyst reports. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Robert W. Baird decreased their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $605.09.

Thermo Fisher Scientific Trading Up 2.4%

Shares of TMO stock opened at $513.53 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a fifty day moving average of $473.08 and a 200-day moving average of $518.47. Thermo Fisher Scientific Inc. has a 52-week low of $403.36 and a 52-week high of $643.99. The stock has a market cap of $190.84 billion, a price-to-earnings ratio of 28.23, a P/E/G ratio of 2.22 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.